LianBio Q3 net loss $21.9M; cash $331.8M; mavacamten Phase 3 data expected mid-2023

LianBio

2022-Q3 EPS reported -$0.85

Net loss of $21.9M for Q3 2022 vs $13.1M YoY; R&D expenses $8.3M, G&A $16.3M.
Cash, cash equivalents, securities $331.8M at Sep 30, 2022, down from $403.2M Dec 31, 2021; runway into 2H 2024.
Mavacamten Phase 3 EXPLORER-CN data expected mid-2023; NDA submitted in Hong Kong; included in Chinese HCM guidelines.
TP-03 Phase 3 LIBRA trial for Demodex blepharitis initiated in China; data expected Q4 2023; US NDA accepted, PDUFA Aug 25, 2023.
Phase 3 NANORAY-312 (NBTXR3) for head & neck cancer initiated in Asia; Phase 1 BBP-398 dosing begun.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

LianBio reported third quarter ended September 30, 2022 results: net income $21.9 million.

Period: third quarter ended September 30, 2022
Net income: $21.9 million
Result: reported results

Exact text from the filing

LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

View on SEC.gov

21 earnings releases filed in the last 30 days. Browse all earnings releases →

LianBio filing history →

Source: SEC EDGAR

accession 0001831283-22-000071

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.